Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Encainide hydrochloride
Drug ID BADD_D00769
Description All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
Indications and Usage Encainide is a class Ic antiarrhythmic agent which was used for management of irregular heartbeats, such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.
Marketing Status approved; investigational; withdrawn
ATC Code C01BC08
DrugBank ID DB01228
KEGG ID D03991
MeSH ID D016700
PubChem ID 48040
TTD Drug ID D06PAZ
NDC Product Code Not Available
UNII 4CH7J36N9S
Synonyms Encainide | Encainide, (+)-Isomer | Enkaid | MJ-9067 | MJ 9067 | MJ9067 | Encainide Hydrochloride | Encainide Hydrochloride, (+-)-Isomer | Encainide, (-)-Isomer
Chemical Information
Molecular Formula C22H29ClN2O2
CAS Registry Number 66794-74-9
SMILES CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukopenia01.02.02.001--Not Available
Malaise08.01.01.003--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Photophobia17.17.02.006; 06.01.01.004--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Sensory disturbance17.02.07.006--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular tachycardia02.03.04.010--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Transaminases increased13.03.04.036--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Antinuclear antibody positive13.06.01.003--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
The 2th Page    First    Pre   2    Total 2 Pages